Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Michigan Cancer Center |
---|---|
Information provided by: | University of Michigan Cancer Center |
ClinicalTrials.gov Identifier: | NCT00141713 |
Etanercept (Enbrel) will be added to standard therapy for acute Graft-versus-Host Disease to see if the effectiveness of standard therapy can be improved.
Condition | Intervention | Phase |
---|---|---|
Graft-Versus-Host Disease |
Drug: Etanercept |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease |
Enrollment: | 40 |
Study Start Date: | October 2003 |
Estimated Study Completion Date: | September 2012 |
Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
etanercept treatment for GVHD
|
Drug: Etanercept
Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
|
The standard treatment for acute graft-versus-host disease is a combination of steroids and tacrolimus or cyclosporine. Previous work has shown that less than 50% of patients respond fully to GVHD. Without a good response, patients often have a prolonged treatment for this disease, often involving hospitalization and sometimes even death.
Etanercept is a drug that blocks a chemical called Tumor Necrosis Factor (TNF) from causing damage to tissue. Etanercept (Enbrel) will be added to help improve the response to standard treatment for graft-versus-host disease (GVHD).
This is an experimental research project. It is not known whether the etanercept will actually improve the body's response to graft-versus-host disease. This treatment is meant to determine if etanercept will improve your response to treatment of GVHD.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Michigan | |
The University of Michigan Comprehensive Cancer Center | |
Ann Arbor, Michigan, United States, 48109 |
Principal Investigator: | John E. Levine, MS MD | The University of Michigan |
Responsible Party: | Umiversity of Michigan ( John Levine, MD / associate professor pediatrics ) |
Study ID Numbers: | UMCC 3-37 |
Study First Received: | August 30, 2005 |
Last Updated: | January 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00141713 |
Health Authority: | United States: Food and Drug Administration |
Methylprednisolone Graft versus host disease Prednisolone Methylprednisolone acetate Graft vs Host Disease |
Prednisolone acetate TNFR-Fc fusion protein Methylprednisolone Hemisuccinate Homologous wasting disease |
Anti-Inflammatory Agents Immunologic Factors Immune System Diseases Physiological Effects of Drugs Gastrointestinal Agents Immunosuppressive Agents Pharmacologic Actions Analgesics, Non-Narcotic |
Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |